ArticleThe Journal of experimental medicine2021

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10.

Courtney Mowat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.